Drug Trial Radar · NCT04923607
Phase I Clinical Trial of TQC2731 Injection
Last checked: Nov 20, 2026Latest source record: Jun 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
96
Planned (sponsor's estimate)
Start
Jun 25, 2021
Primary completion
Aug 25, 2023
Study completion Aug 25, 2023
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 11, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is the first-in-human phase 1 trial of TQC2731 injection in healthy subjects and in patients with severe asthma to evaluate the safety, tolerability, pharmacokinetic characteristics and immunogenicity.
Conditions
- Asthma Severe Persistent Controlled
Interventions
TQC2731Drug
TQC2731 injection
PlaceboDrug
Matching placebo with no active ingredients
Primary outcomes
What the sponsor says the trial is designed to measure.
- (healthy subject)Number of participants with abnormal clinical symptomsTime frame: appropriatly up to Day 253
- (healthy subject)Number of participants with abnormal physical examinationTime frame: appropriatly up to Day 253
- (healthy subject)Number of participants with abnormal vital signsTime frame: appropriatly up to Day 253
- (asthma subject)Number of participants with abnormal laboratory examinationsTime frame: appropriatly up to Day 253
Locations
1 site in 1 country. Site status is shown where the registry gives one.
First Affiliated Hospital of Zhengzhou University
Henan, Zhengzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.